Sánchez Lastra, Miguel AdrianoPozo Cruz, Borja delTarp, JakobEirik Dalene, KnutDing Ding, Tormod S.Ekelund, Ulf2026-10-312026-10-312026Sanchez-Lastra, M. A., Del Pozo Cruz, B., Tarp, J., Dalene, K. E., Nilsen, T. S., Ding, D., & Ekelund, U. (2026). Dose‒response associations of self-reported and device-measured physical activity with major adverse cardiovascular events in people with prevalent diseases. Journal of Sport and Health Science, 15, 101116. https://doi.org/10.1016/j.jshs.2025.1011162095-25462213-2961https://hdl.handle.net/11268/17524Purpose: To investigate the dose response associations of self-reported and device-measured physical activity with major adverse cardiovascular events (MACE) and cardiovascular disease (CVD) mortality in individuals with a history of CVD, type 2 diabetes mellitus (T2DM), or cancer. Methods: We analyzed data from 34,183 UK Biobank participants (CVD: n=8703; T2DM: n=11,623; cancer: n=13,857; age=60.0§7.1 years, mean § SD; 45.3% women). Physical activity was assessed using self-reports and wrist-worn accelerometers in a subsample (n= 6077). Dose‒response associations with MACE and CVD mortality were evaluated using Fine-Gray competing-risk models with penalized splines, adjusting for confounders. Results: During a median follow-up of 13.1 years, 8729 MACE and 982 CVD deaths were recorded. Self-reported physical activity showed nonlinear inverse associations with MACE, with the optimal dose (nadir) observed at 4000 MET-min/week in CVD (hazard ratio (HR)=0.95) and cancer (HR =0.92) and 6000 MET-min/week in T2DM (HR=0.91), compared to participants in the 5th centiles of activity. For CVD mortality, the optimal dose was observed at 5000 MET-min/week in CVD (HR=0.86) and cancer (HR=0.62), respectively. Device-measured moderate-to-vigorous intensity physical activity showed stronger dose‒response associations with MACE for T2DM (optimal dose observed at 200 min/week, HR=0.88) and cancer (optimal dose at 700min/week, HR=0.27, wide confidence intervals). Conclusion: Physical activity could reduce MACE risk in people with a history of CVD, T2DM, or cancer. While a similar shape of doseresponse patterns was observed across these groups, self-reported data suggested the minimal effective dose might exceed current World Health Organization recommendations. However, device-measured data supported existing guidelines for people with T2DM and cancer survivors.engAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Saludjournal article10.1016/j.jshs.2025.101116open accessEnfermedad cardiovascularDeporteGoal 3: Ensure healthy lives and promote well-being for all at all ages